Home Carbonyls Glycine, N-[(1R)-2-[(2S)-2-[[[[4-(aminoiminomethyl)phenyl]methyl]amino]carbonyl]-1-azetidinyl]-1-cyclohexyl-2-oxoethyl]-

Glycine, N-[(1R)-2-[(2S)-2-[[[[4-(aminoiminomethyl)phenyl]methyl]amino]carbonyl]-1-azetidinyl]-1-cyclohexyl-2-oxoethyl]-

CAS No.:
159776-70-2
Catalog Number:
AG001RE6
Molecular Formula:
C22H31N5O4
Molecular Weight:
429.5126
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
Product Description
Catalog Number:
AG001RE6
Chemical Name:
Glycine, N-[(1R)-2-[(2S)-2-[[[[4-(aminoiminomethyl)phenyl]methyl]amino]carbonyl]-1-azetidinyl]-1-cyclohexyl-2-oxoethyl]-
CAS Number:
159776-70-2
Molecular Formula:
C22H31N5O4
Molecular Weight:
429.5126
MDL Number:
MFCD00945676
IUPAC Name:
2-[[(1R)-2-[(2S)-2-[(4-carbamimidoylphenyl)methylcarbamoyl]azetidin-1-yl]-1-cyclohexyl-2-oxoethyl]amino]acetic acid
InChI:
InChI=1S/C22H31N5O4/c23-20(24)16-8-6-14(7-9-16)12-26-21(30)17-10-11-27(17)22(31)19(25-13-18(28)29)15-4-2-1-3-5-15/h6-9,15,17,19,25H,1-5,10-13H2,(H3,23,24)(H,26,30)(H,28,29)/t17-,19+/m0/s1
InChI Key:
DKWNMCUOEDMMIN-PKOBYXMFSA-N
SMILES:
NN=Cc1ccc(cc1)CNC(=O)[C@@H]1CCN1C(=O)[C@@H](C1CCCCC1)NCC(=O)O
UNII:
2A9QP32MD4
Properties
Complexity:
671  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
2  
Defined Bond Stereocenter Count:
0
Exact Mass:
429.238g/mol
Formal Charge:
0
Heavy Atom Count:
31  
Hydrogen Bond Acceptor Count:
6  
Hydrogen Bond Donor Count:
5  
Isotope Atom Count:
0
Molecular Weight:
429.521g/mol
Monoisotopic Mass:
429.238g/mol
Rotatable Bond Count:
9  
Topological Polar Surface Area:
149A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
-1  
Literature
Title Journal
Design, synthesis, and SAR of a series of activated protein C (APC) inhibitors with selectivity against thrombin for the treatment of haemophilia. Bioorganic & medicinal chemistry letters 20140201
Pharmacophore fingerprint-based approach to binding site subpocket similarity and its application to bioisostere replacement. Journal of chemical information and modeling 20120827
Dabigatran and dabigatran ethyl ester: potent inhibitors of ribosyldihydronicotinamide dehydrogenase (NQO2). Journal of medicinal chemistry 20120426
Serine proteases mediate inflammatory pain in acute pancreatitis. American journal of physiology. Gastrointestinal and liver physiology 20110601
The influence of direct thrombin inhibitors on the formation of platelet-leukocyte aggregates and tissue factor expression. Thrombosis research 20101001
Antithrombotic and anticoagulant profiles of TAK-442, a novel factor Xa inhibitor, in a rabbit model of venous thrombosis. Journal of cardiovascular pharmacology 20100801
Investigation of the involvement of P-glycoprotein and multidrug resistance-associated protein 2 in the efflux of ximelagatran and its metabolites by using short hairpin RNA knockdown in Caco-2 cells. Drug metabolism and disposition: the biological fate of chemicals 20100301
Anti-thrombin therapy during warm ischemia and cold preservation prevents chronic kidney graft fibrosis in a DCD model. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20100101
Direct thrombin inhibitor prevents delayed graft function in a porcine model of renal transplantation. Transplantation 20090615
Compounds binding to the S2-S3 pockets of thrombin. Journal of medicinal chemistry 20090514
The effect of ex vivo anticoagulants on whole blood platelet aggregation. Platelets 20090201
Online capillary solid phase extraction and liquid chromatographic separation with quantitative tandem mass spectrometric detection (SPE-LC-MS/MS) of ximelagatran and its metabolites in a complex matrix. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20090115
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1. Journal of medicinal chemistry 20081009
Pro-inflammatory response and adverse drug reactions: mechanisms of action of ximelagatran on chemokine and cytokine activation in a monocyte in vitro model. Toxicology in vitro : an international journal published in association with BIBRA 20080901
Effect of low and high dose melagatran and other antithrombotic drugs on platelet aggregation. Journal of thrombosis and thrombolysis 20080401
Melagatran for thromboprophylaxis after mechanical valve implantation: results in a heterotopic porcine model. The Journal of thoracic and cardiovascular surgery 20070801
The direct thrombin inhibitor ximelagatran/melagatran: a systematic review on clinical applications and an evidence based assessment of risk benefit profile. Expert opinion on drug safety 20070701
Antithrombotic and anticoagulant effects of the direct thrombin inhibitor dabigatran, and its oral prodrug, dabigatran etexilate, in a rabbit model of venous thrombosis. Journal of thrombosis and haemostasis : JTH 20070601
Effects of thrombin inhibition with melagatran on renal hemodynamics and function and liver integrity during early endotoxemia. American journal of physiology. Regulatory, integrative and comparative physiology 20070301
Thermodynamic inhibition profile of a cyclopentyl and a cyclohexyl derivative towards thrombin: the same but for different reasons. Angewandte Chemie (International ed. in English) 20070101
Effects of melagatran on activated partial thromboplastin time and on ecarin clotting time in cord versus adult plasma. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 20061101
[Clinical use of a new class of anticoagulant drugs: the direct thrombin inhibitors]. Giornale italiano di cardiologia (2006) 20061101
Orally active thrombin inhibitors. Part 1: optimization of the P1-moiety. Bioorganic & medicinal chemistry letters 20060515
Antithrombotic effects of ximelagatran plus acetylsalicylic acid (ASA) and clopidogrel plus ASA in a human ex vivo arterial thrombosis model. Thrombosis and haemostasis 20060301
Ximelagatran: direct thrombin inhibitor. Vascular health and risk management 20060301
A combination of a thrombin inhibitor and dexamethasone prevents the development of experimental disseminated intravascular coagulation in rats. Thrombosis research 20060101
Comparable pharmacokinetics and pharmacodynamics of melagatran in Japanese and caucasian volunteers after oral administration of the direct thrombin inhibitor ximelagatran. Clinical pharmacokinetics 20060101
Population pharmacokinetics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, in atrial fibrillation patients receiving long-term anticoagulation therapy. Clinical pharmacokinetics 20060101
Assessment of bleeding after concomitant administration of antiplatelet and anticoagulant agents in lower limb arthroplasty. Pathophysiology of haemostasis and thrombosis 20060101
Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation. Thrombosis and haemostasis 20051101
[The new antithrombotic agents]. Presse medicale (Paris, France : 1983) 20051022
The antithrombotic effect of melagatran in combination with clopidogrel and/or aspirin (carotid artery primary thrombosis study). Journal of cardiovascular pharmacology 20051001
Long-term treatment with ximelagatran, an oral direct thrombin inhibitor, persistently reduces the coagulation activity after a myocardial infarction. Journal of thrombosis and haemostasis : JTH 20051001
Prevention of clot formation during haemodialysis using the direct thrombin inhibitor melagatran in patients with chronic uraemia. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20050901
Melagatran anticoagulation during haemodialysis--'Primum non nocere'. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20050901
New antithrombotics in the prevention of thromboembolic disease. European journal of internal medicine 20050801
Drug insight: an overview of current anticoagulation therapy after heart valve replacement. Nature clinical practice. Cardiovascular medicine 20050801
Pharmacokinetics and pharmacodynamics of ximelagatran. Seminars in vascular medicine 20050801
Low potential for interactions between melagatran/ximelagatran and other drugs, food, or alcohol. Seminars in vascular medicine 20050801
Comparison of two different ecarin clotting time methods. Journal of thrombosis and thrombolysis 20050801
Additive effects of anticoagulants: recombinant human activated protein C and heparin or melagatran, in tissue factor-activated umbilical-cord plasma. Thrombosis and haemostasis 20050701
Recombinant human activated protein C, heparin and melagatran in umbilical cord versus adult plasma. Acta paediatrica (Oslo, Norway : 1992) 20050701
The effects of ximelagatran and warfarin on the prophylaxis of a caval vein thrombosis and bleeding in the anaesthetized rat. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 20050601
[Thromboprophylaxis in hip and knee arthroplasty. Are the new anticoagulants better than those previously used?]. Ugeskrift for laeger 20050523
Different antithrombotic properties of factor Xa inhibitor and thrombin inhibitor in rat thrombosis models. European journal of pharmacology 20050502
The oral direct thrombin inhibitor, ximelagatran, an alternative for anticoagulant treatment during the puerperium and lactation. BJOG : an international journal of obstetrics and gynaecology 20050501
Ximelagatran and melagatran vs. low-molecular-weight heparin in major orthopedic surgery: relationship between efficacy and safety and timing of initial administration. Journal of thrombosis and haemostasis : JTH 20050501
The direct thrombin inhibitor melagatran/ximelagatran. The Medical journal of Australia 20050307
Anticoagulant action of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, in umbilical cord and adult plasma: an in vitro examination. Thrombosis research 20050101
Ximelagatran--a promising new drug in thromboembolic disorders. Current pharmaceutical design 20050101
[Effective thrombosis prophylaxis with melagatran]. Zeitschrift fur Orthopadie und ihre Grenzgebiete 20050101
[New anticoagulants in clinical practice]. Orvosi hetilap 20041205
Advances in anticoagulation therapy: the role of selective inhibitors of factor Xa and thrombin in thromboprophylaxis after major orthopedic surgery. Seminars in thrombosis and hemostasis 20041201
Prevention of venous thromboembolism after orthopedic surgery: the EXPRESS study. Journal of thrombosis and haemostasis : JTH 20041101
The direct thrombin inhibitor melagatran/ximelagatran. The Medical journal of Australia 20041018
Drotrecogin alfa activated (recombinant human activated protein C) in combination with heparin or melagatran: effects on prothrombin time and activated partial thromboplastin time. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 20041001
Thrombin inhibitor reduces myocardial infarction in apoE-/- x LDLR-/- mice. American journal of physiology. Heart and circulatory physiology 20040801
Significantly lower need for blood transfusions associated with post-operatively initiated subcutaneous melagatran/oral ximelagatran compared with enoxaparin. Thrombosis and haemostasis 20040801
No pharmacokinetic or pharmacodynamic interaction between atorvastatin and the oral direct thrombin inhibitor ximelagatran. Journal of clinical pharmacology 20040801
No pharmacokinetic or pharmacodynamic interaction between digoxin and the oral direct thrombin inhibitor ximelagatran in healthy volunteers. Journal of clinical pharmacology 20040801
Drotrecogin alfa (activated, Xigris) in combination with heparin or melagatran: an in vitro investigation. Journal of thrombosis and thrombolysis 20040801
[Prevention and treatment of deep vein thrombosis with ximelagatran]. Deutsche medizinische Wochenschrift (1946) 20040723
The beginning of the end of warfarin? The Medical journal of Australia 20040607
The therapeutic potential of ximelagatran to become the anticoagulant of choice in medicine: a review of recently completed clinical trials. Expert opinion on pharmacotherapy 20040601
Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers. Thrombosis and haemostasis 20040601
[Ximelagatran/Melagatran. Perspectives for new oral antithrombin drugs]. Journal des maladies vasculaires 20040501
Combined effects of melagatran and eptifibatide on platelet aggregation inhibition but not thrombin generation inhibition. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 20040301
Recombinant factor VIIa as an antidote for anticoagulant treatment. Seminars in hematology 20040101
Ximelagatran/Melagatran: a review of its use in the prevention of venous thromboembolism in orthopaedic surgery. Drugs 20040101
Inhibition of thrombin-induced feedback activation of factor V: a potential pathway for inhibition of thrombin generation by melagatran. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 20040101
[Low molecular weight heparin, fondaparinux and melagatran: new data and clinical studies]. Pharmazie in unserer Zeit 20040101
Oral anticoagulation: preparing for change. Journal of the American Medical Directors Association 20040101
The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. Journal of thrombosis and haemostasis : JTH 20031201
[Melagatran and ximelagatran. Pharmacologic characteristics and anesthesiological aspects]. Der Anaesthesist 20031201
Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects. European journal of clinical pharmacology 20031001
Oral direct thrombin inhibitors in clinical development. Journal of internal medicine 20031001
Pharmacokinetics and anticoagulant effect of the direct thrombin inhibitor melagatran following subcutaneous administration to healthy young men. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 20031001
Improving antithrombotic treatment in patients after myocardial infarction. Lancet (London, England) 20030906
Three vehicle formulations for melagatran, a direct thrombin inhibitor, evaluated in a vena cava thrombosis model in the rat. Biopharmaceutics & drug disposition 20030901
Determination of melagatran in rabbit plasma by high-performance liquid chromatography with automated column switching. Biomedical chromatography : BMC 20030901
Pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, are not influenced by acetylsalicylic acid. European journal of clinical pharmacology 20030801
The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review. Thrombosis research 20030715
Clinical experience of melagatran/ximelagatran in major orthopaedic surgery. Thrombosis research 20030715
Medical indications and considerations for future clinical decision making. Thrombosis research 20030715
Effects of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, and dalteparin on the endogenous thrombin potential in venous blood from healthy male subjects. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 20030701
D-Phe-Pro-Arg type thrombin inhibitors: unexpected selectivity by modification of the P1 moiety. Bioorganic & medicinal chemistry letters 20030616
The influence of direct and antithrombin-dependent thrombin inhibitors on the procoagulant and anticoagulant effects of thrombin. Thrombosis research 20030601
In vitro effect of melagatran and lepirudin on clot-bound thrombin. Thrombosis research 20030601
Characterization of in vitro biotransformation of new, orally active, direct thrombin inhibitor ximelagatran, an amidoxime and ester prodrug. Drug metabolism and disposition: the biological fate of chemicals 20030501
The METHRO trials. Expert opinion on investigational drugs 20030501
[Chromogenic substrate as antidote against the thrombin inhibitor Melagatran?]. Hamostaseologie 20030501
Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects. European journal of clinical pharmacology 20030501
Predicting the pharmacology of thrombin inhibitors. Journal of thrombosis and haemostasis : JTH 20030501
Orally active direct thrombin inhibitors. Seminars in vascular medicine 20030501
Melagatran attenuates fibrin and platelet deposition in a porcine coronary artery over-stretch injury model. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 20030401
Synthesis of novel thrombin inhibitors. Use of ring-closing metathesis reactions for synthesis of P2 cyclopentene- and cyclohexenedicarboxylic acid derivatives. Journal of medicinal chemistry 20030327
[The first oral thrombin inhibitor. Competition to heparins and marcumar?]. MMW Fortschritte der Medizin 20030306
The benefit-to-risk profile of melagatran is superior to that of hirudin in a rabbit arterial thrombosis prevention and bleeding model. Journal of thrombosis and haemostasis : JTH 20030301
Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Thrombosis and haemostasis 20030201
Inhibition of endothelial cell-mediated generation of activated protein C by direct and antithrombin-dependent thrombin inhibitors. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 20030201
Thrombin-induced platelet activation and its inhibition by anticoagulants with different modes of action. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 20030201
Determination of ximelagatran, an oral direct thrombin inhibitor, its active metabolite melagatran, and the intermediate metabolites, in biological samples by liquid chromatography-mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030115
[New anticoagulants -- their clinical significance]. Therapeutische Umschau. Revue therapeutique 20030101
Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. Clinical pharmacokinetics 20030101
No influence of ethnic origin on the pharmacokinetics and pharmacodynamics of melagatran following oral administration of ximelagatran, a novel oral direct thrombin inhibitor, to healthy male volunteers. Clinical pharmacokinetics 20030101
No influence of obesity on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran. Clinical pharmacokinetics 20030101
Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysis. Clinical pharmacokinetics 20030101
Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran. Clinical pharmacokinetics 20030101
No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. Clinical pharmacokinetics 20030101
Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions. Clinical pharmacokinetics 20030101
[Treatment and prevention of venous thromboembolic events: present and future antithrombotic agents]. Bulletin de l'Academie nationale de medecine 20030101
Effects of the oral direct thrombin inhibitor ximelagatran on p-selectin expression and thrombin generation in atrial fibrillation. Pathophysiology of haemostasis and thrombosis 20030101
Effects of lepirudin, argatroban and melagatran and additional influence of phenprocoumon on ecarin clotting time. Thrombosis research 20030101
Novel anticoagulants for the prevention and treatment of venous thromboembolism. Wiener medizinische Wochenschrift (1946) 20030101
Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet (London, England) 20021109
Influence of lepirudin, argatroban, and melagatran on prothrombin time and additional effect of oral anticoagulation. Clinical chemistry 20021001
Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis. Thrombosis research 20020815
Effects of ximelagatran, the oral form of melagatran, in the treatment of caval vein thrombosis in conscious rats. Thrombosis research 20020815
Monitoring of anticoagulant effects of direct thrombin inhibitors. Seminars in thrombosis and hemostasis 20020801
Comparative antithrombotic potencies of direct thrombin inhibitors and low-molecular-weight heparins in an ex vivo human experimental thrombosis model. Seminars in thrombosis and hemostasis 20020801
Inhibition of thrombin abrogates the instant blood-mediated inflammatory reaction triggered by isolated human islets: possible application of the thrombin inhibitor melagatran in clinical islet transplantation. Diabetes 20020601
Noncovalent tripeptidic thrombin inhibitors incorporating amidrazone, amine and amidine functions at P1. Bioorganic & medicinal chemistry letters 20020408
Maximized hemostasis. Thrombosis and haemostasis 20020401
Local proCPU (TAFI) activation during thrombolytic treatment in a dog model of coronary artery thrombosis can be inhibited with a direct, small molecule thrombin inhibitor (melagatran). Thrombosis and haemostasis 20020401
Factor V Leiden (G1691A) and prothrombin gene G20210A mutations as potential risk factors for venous thromboembolism after total hip or total knee replacement surgery. Thrombosis and haemostasis 20020401
Prophylaxis of venous thromboembolism with subcutaneous melagatran in total hip or total knee replacement: results from Phase II studies. Thrombosis research 20020301
A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery. Thrombosis and haemostasis 20020201
Determination of melagatran, a novel, direct thrombin inhibitor, in human plasma and urine by liquid chromatography-mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20020105
Melagatran. Exanta, H 319/68. Drugs in R&D 20020101
Effect of phenprocoumon on monitoring of lepirudin, argatroban, melagatran and unfractionated heparin with the PiCT method. Pathophysiology of haemostasis and thrombosis 20020101
Factorising ligand affinity: a combined thermodynamic and crystallographic study of trypsin and thrombin inhibition. Journal of molecular biology 20011026
Effect of melagatran on prothrombin time assays depends on the sensitivity of the thromboplastin and the final dilution of the plasma sample. Thrombosis and haemostasis 20010801
Anticoagulation: the present and future. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 20010701
Advances in the development of thrombin inhibitors. Expert opinion on investigational drugs 20010501
[Direct thrombin antagonists]. Herz 20010401
The effects of oral and intravenous direct thrombin inhibitors on the size of photochemically induced cortical infarction in rats. Thrombosis research 20010315
Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor. Thrombosis research 20010201
Effects of agents, used to treat bleeding disorders, on bleeding time prolonged by a very high dose of a direct thrombin inhibitor in anesthesized rats and rabbits. Thrombosis research 20010201
The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thrombosis research 20010201
[New thrombolytic agents]. Medizinische Monatsschrift fur Pharmazeuten 20010201
[Treatment of deep vein thrombosis. Current and future questions]. Bulletin de l'Academie nationale de medecine 20010101
[Thrombosis in spite of warfarin--what should be done?]. Duodecim; laaketieteellinen aikakauskirja 20010101
Protease inhibitors: current status and future prospects. Journal of medicinal chemistry 20000210
Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. Thrombosis and haemostasis 19980101
Properties